Repligen (NASDAQ:RGEN) Upgraded at StockNews.com

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Thursday.

Several other brokerages also recently weighed in on RGEN. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Royal Bank of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. TD Cowen began coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Stock Performance

RGEN stock traded up $0.23 during mid-day trading on Thursday, hitting $133.95. The company had a trading volume of 167,100 shares, compared to its average volume of 726,791. The firm has a market cap of $7.52 billion, a PE ratio of -262.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The stock's fifty day moving average price is $134.55 and its two-hundred day moving average price is $145.43. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period last year, the business posted $0.28 earnings per share. Repligen's quarterly revenue was up 10.4% compared to the same quarter last year. On average, analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Repligen

A number of hedge funds have recently added to or reduced their stakes in RGEN. Signaturefd LLC increased its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. purchased a new position in shares of Repligen in the 4th quarter valued at $29,000. Raiffeisen Bank International AG purchased a new stake in shares of Repligen in the fourth quarter worth about $29,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Repligen during the 4th quarter valued at about $40,000. Finally, Center for Financial Planning Inc. lifted its position in Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 193 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.